ScreenerHero

LKFT Lakefront Biotherapeutics NV

NAS · US · Healthcare · Biotechnology · lakefrontbio.com
30.00USD+2.32%Mkt Cap: 1.96B $P/E: 2.85

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a ph…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.96B USD
Enterprise Value36.27B USD
Revenue (TTM)990.57M USD
Gross Profit1.08B USD
Net Income (TTM)320.88M USD
Revenue/Share0.75 USD
Last Price30.00 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.85
P/E (Forward)-24.58
PEG—
EV/EBITDA63.75
EV/Revenue36.61
P/S1.94
P/B10.41
EPS (TTM)10.52
EPS (Forward)-1.19
52W Range
25.6836% of range37.78
52W High37.78 USD
52W Low25.68 USD
Profitability
Gross Margin97.33%
Oper. Margin-359.30%
EBITDA Margin57.43%
Profit Margin28.85%
ROE9.92%
ROA9.42%
Growth
Revenue Growth-81.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-257.46M USD
CapEx (TTM)13.86M USD
FCF Margin13.95%
FCF Yield7.04%
Net Debt-2.23B USD
Net Debt/EBITDA-3.93
Balance Sheet
Debt/Equity0.00
Current Ratio32.84
Quick Ratio32.65
Book Value/Sh2.82 USD
Cash/Share1.71 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)30.33 USD
Upside (mean)+1.1%
Target Range21.39 USD – 44.27 USD
21.39+1.1% to mean44.27
# Analysts3
Ownership
Shares Out.65.48M
Float474.38M
Insiders25.45%
Institutions23.63%
Short Interest
Short Ratio13.1d
Short % Float8.52%
Short % Out.5.21%
Shares Short3.41M
Short (prev mo.)2.97M
Technical
SMA 5028.34 (+5.8%)
SMA 20030.13 (-0.4%)
Beta0.06
S&P 52W Chg15.78%
Avg Vol (30d)283.34K
Avg Vol (10d)341.86K
Technical Indicators
RSI (14)57.7
MACD0.3584
MACD Signal0.3369
MACD Hist.+0.0216
BB Upper31.42 USD
BB Middle28.91 USD
BB Lower26.39 USD
BB Width17.39%
ATR (14)0.8540 USD
Vol Ratio (20d)1.18x